Listen to this article. Choose between:

You’re halfway through lunch when someone mentions a medication whose name you haven’t quite caught. You recognize Ozempic, perhaps from our earlier look at GLP-1, but now there is another name at the table: tirzepatide. Before long, the conversation has moved to appetite, blood sugar, and weight, while the difference between the medicines has slipped out of view. You could leave with the impression that the names describe roughly the same thing, with each new arrival offering a little more of it. That is an understandable way to follow a conversation filled with unfamiliar terms, especially when the medicines are grouped under the convenient label “GLP-1 drugs.” Yet the names become easier to follow once you look at what each medicine is designed to act on, because the change involves more than a new name on the same approach.

Ozempic contains semaglutide, which activates the receptor for GLP-1, a hormone released from the gut after eating. Receptors are proteins that respond to chemical signals and trigger activity within cells. Tirzepatide activates the GLP-1 receptor as well, but it also acts on the receptor for another gut hormone called GIP. You can think of these receptors as separate controls on a dashboard, each influencing different aspects of the body's response. Activating both introduces possibilities that aren't available when a medicine targets only one. Throughout this series, we'll describe single-receptor treatment as a first generation and tirzepatide's dual-receptor approach as a second, recognizing that these labels describe differences in design rather than guarantees of greater effectiveness or fewer side effects. To understand why researchers began exploring this approach, we need to look at what normally happens after a meal.

Return to that lunch for a moment, this time looking beyond the names being discussed. As nutrients from the meal reach the intestine, specialized cells release hormones that help coordinate what happens next. These are chemical signals carried through the blood, linking food in the gut with activity elsewhere in the body. GLP-1 is one of them. It helps the pancreas release insulin when blood glucose rises, and it also has roles in appetite and the movement of food out of the stomach. Insulin, in turn, helps regulate how the body uses and stores nutrients, including glucose, the sugar circulating in the blood. The gut is therefore involved in more than digestion and absorption. It also contributes signals that help match the response to the nutrients arriving from a meal. GIP is another hormone involved in this coordination between the intestine and the rest of the body.

GIP stands for glucose-dependent insulinotropic polypeptide, a name that is easier to understand once you unpack its central idea. “Insulinotropic” means that it promotes insulin release, while “glucose-dependent” means that this effect depends on the glucose level. When glucose is elevated, GIP can strengthen the pancreas’s insulin response. Think of it as an amplifier: it increases the response to a signal already present, in this case the rise in glucose. GLP-1 shares that ability, which is why both hormones are called incretins. The term describes their contribution from the gut to insulin secretion after food is consumed. They come from different specialized cells in the intestinal lining: GIP from cells called K cells, and GLP-1 from L cells. The letters are simply names for the cell types. The useful point is that the normal insulin response to a meal draws on more than one gut hormone.

GIP also provides a way into another part of the meal response: how nutrients are handled by fat tissue. In a small experiment involving 8 healthy, lean adults, researchers infused GIP while insulin and glucose were held at raised levels. Under those conditions, blood flow and glucose uptake in abdominal fat tissue increased, and the findings indicated greater storage of fatty acids, the building blocks of fats. This was a short experiment under controlled conditions, so it cannot tell us what prolonged GIP treatment would do to someone’s weight. It does show why describing GIP only as an insulin signal leaves part of its biology out. Handling energy includes storing it, and a hormone’s role in that process cannot be reduced to a label such as “fat-burning” or “fattening.” GIP’s normal role in handling a meal is the starting point for understanding why its receptor became a target for drug development.

One place to see the difference is in another pancreatic hormone, glucagon. Despite the similar name, glucagon is different from GLP-1. It helps raise blood glucose by signaling the liver to release glucose into the circulation. GLP-1 can suppress glucagon release when glucose is elevated, complementing its support for insulin secretion. GIP has a different pattern: it can stimulate glucagon release when glucose is normal or low. The same hormone that helps strengthen insulin release under higher-glucose conditions can therefore have another effect under different conditions. That is useful context when thinking about a meal, because the task is not simply to push blood sugar as low as possible. Glucose regulation involves responses that change with the glucose level, and sharing an effect on insulin does not mean that two hormones have identical roles across that changing range.

The differences also extend beyond the pancreas. Consider the feeling of deciding that you have eaten enough, or how long food remains in the stomach before moving onward. GLP-1 has effects on appetite and can slow the movement of food out of the stomach, alongside its effects on insulin and glucagon. These are related parts of the response to eating, but they are not the same process. Feeling less hungry, releasing insulin, and changing stomach emptying describe different outcomes, even if they occur around the same meal. GIP’s place in the incretin family does not establish that it produces the same effects on all three. Its insulin action is well established; explaining how GIP receptor activation contributes to appetite and weight during drug treatment requires evidence beyond that shared insulin function. The name of the hormone family cannot answer those questions on its own.

The differences between GLP-1 and GIP help explain why researchers became interested in activating both receptors. Although the hormones share an ability to support insulin secretion, their effects elsewhere in the body are not identical. Changes in pancreatic activity may help explain improvements in glucose regulation without necessarily accounting for reduced hunger, just as changes in fat tissue cannot independently predict what happens to body weight. These processes are connected, but their relationships are complex enough that the effects of activating both receptors must be investigated rather than assumed.

Tirzepatide turns that question into a particular kind of drug design. It is a peptide, a chain of building blocks called amino acids, engineered so that the same molecule can activate both the GIP receptor and the GLP-1 receptor. It does not contain a dose of semaglutide mixed with a dose of GIP. One way to picture the design is as a key shaped to work in two different locks. The locks represent the two receptor types, while the activity triggered inside a cell depends on which receptor has been activated and where that cell is. The analogy explains the shared access, without suggesting that both locks open onto the same room. What matters is that a single molecular design can engage two related signaling systems whose actions overlap in some places and differ in others.

The molecule also changes the duration of that engagement. The hormones released around a meal are part of a changing response to incoming food; a medicine intended for sustained treatment needs a different pattern of exposure. Tirzepatide’s chemical design helps it remain in the body long enough for a once-weekly injection. Semaglutide is also designed to act for longer than the natural hormone, so prolonged action itself is not the distinction between them. Tirzepatide combines that sustained exposure with the ability to activate two receptor types. This is why an injection cannot be understood simply as recreating the hormones present after lunch. The receptor targets come from normal physiology, but the duration and pattern of drug exposure are features of the treatment. Understanding that difference becomes particularly important when interpreting experiments that give people the natural hormones for only a few hours.

The rationale for combining the targets followed from their biology. Since both pathways support insulin secretion, researchers had a reason to investigate whether engaging them together could change glucose control. Their other actions widened the question beyond insulin alone, toward the combined effects on eating and the handling of nutrients. That is a hypothesis to test, rather than a conclusion that follows automatically from adding a receptor target. A useful combination could involve overlapping effects, different effects that complement one another, or responses that depend on the sustained exposure created by the medicine. Describing tirzepatide as a second generation captures this deliberate expansion in strategy. It does not tell us in advance how much weight someone will lose, how their appetite will change, or how well they will tolerate treatment. Those are separate questions, and answering them requires looking at what happened in human studies.

For appetite, researchers can ask people how hungry they feel, but they can also measure what they eat. A 6-week study involving 114 adults without diabetes did both. After 3 weeks, the reduction in calories eaten at a test lunch, where participants could eat as much as they wanted, was about 525 calories greater with tirzepatide than with placebo. Participants also reported changes that included less hunger and fewer food cravings. That finding gives the appetite discussion something more concrete than a general impression of “eating less,” but the setting matters. The number describes the change at a particular laboratory meal, not a daily calorie reduction that can be multiplied across weeks. The participants were also mostly women, with only 1 man in the tirzepatide group. The study helps show an effect on eating, while leaving uncertainty about the size of that effect specifically in men over 50.

Glucose regulation requires a different set of measurements. In a 28-week study of 117 adults with type 2 diabetes, researchers examined insulin secretion and insulin sensitivity, meaning how strongly the body responds to insulin. Tirzepatide improved a measure combining those two functions compared with placebo, and the study also found improvements in both processes. Glucose rises after test meals were reduced as well. This gives a more complete picture than imagining the drug simply making the pancreas release ever more insulin. Glucose can be regulated differently when insulin release and the body’s response to it improve together. These were measurements of physiological function in people with diabetes, however, not an experiment that separated GIP’s contribution from GLP-1’s. They help explain the treated body’s response without identifying which receptor accounts for each part of it.

Body weight brings in a longer timescale. In SURMOUNT-1, a trial involving 2,539 adults with obesity, or overweight accompanied by a weight-related complication, but without diabetes, average weight reductions after 72 weeks ranged from 15.0 percent to 20.9 percent across 3 tirzepatide doses, compared with 3.1 percent with placebo. Those figures describe changes from each group’s starting weight, rather than an additional 15 percent to 21 percent reduction beyond placebo. The estimates were calculated regardless of whether participants stopped their assigned treatment. These are substantial changes, but they remain group averages over a defined treatment period. They are not a forecast for every individual, nor do they establish what happens indefinitely. Most importantly for this article’s question, the trial tested tirzepatide as a complete medicine; it did not measure how much of the weight change belonged to either receptor pathway.

Taken together, these studies provide evidence that tirzepatide influences eating, glucose regulation, and body weight, although each outcome was examined under different conditions and in different populations. The findings establish that the medicine produces meaningful physiological effects, but they don't tell us precisely how those effects arise from its two receptor targets. Understanding that distinction is particularly useful when comparing medicines that act on different combinations of hormones. Researchers have therefore begun investigating GIP more directly, examining what happens when its receptor is activated independently or alongside GLP-1.

An experiment in 17 men with overweight or obesity shows why a simple addition model can be misleading. On separate study days, researchers infused GIP, GLP-1, both hormones together, or saline, while controlling glucose exposure. They then measured how much the men ate at a test meal 4 hours after the infusions began. GLP-1 alone reduced intake compared with saline, but adding GIP did not deepen that reduction. In fact, the men ate more during the combined infusion than during GLP-1 alone. Within that experiment, two hormones did not reduce food intake more than one. Yet the experiment used the natural hormones over a few hours, rather than a long-acting medicine over months. Its result challenges the idea that GIP automatically adds another portion of appetite suppression, without establishing what GIP receptor activation contributes during sustained tirzepatide treatment.

A newer study approached the question from another direction, using an experimental long-acting medicine that activates only the GIP receptor. The early-stage trial enrolled 85 people across several groups, including healthy volunteers and adults with type 2 diabetes. Some groups received a single dose, while others received 4 weekly doses. In the highest-dose group with diabetes, average weight remained about 3.1 kilograms below the starting weight 5 weeks after the last dose, compared with about 0.4 kilograms in the placebo group. That is an early signal from a small group, not an estimate of what GIP contributes to tirzepatide. It also does not establish lasting weight control or explain the route through which the change occurred. What it adds is human evidence that sustained GIP receptor activation can affect weight, so the older infusion result cannot settle the question by itself.

The apparent difference between these findings becomes more understandable when we consider how the hormones were administered. A few hours of exposure to naturally occurring GIP and GLP-1 is not equivalent to sustained activation of their receptors by an engineered medicine. The populations also differed, including their metabolic health, making direct comparisons difficult. Rather than assigning separate portions of tirzepatide's effects to GLP-1 and GIP, the evidence suggests that the contribution of each pathway may depend on the duration of exposure, the physiological conditions, and the outcome being measured. GIP is therefore a credible component of the treatment strategy, even though its precise contribution remains unresolved. Understanding that complexity also helps explain why the development of new medicines involves more than simply adding receptor targets.

The search for a new generation of medicines involves more than increasing the average change on the scale. Researchers also want treatments that people can tolerate more comfortably, and the two goals need to be measured separately. Tirzepatide illustrates why. In SURMOUNT-1, gastrointestinal effects were the most common adverse events, usually mild or moderate and occurring mainly while doses were being increased. Some participants stopped treatment because of adverse events. A medicine can therefore produce substantial weight loss while still presenting tolerability problems. That does not erase the measured benefit, but it does mean that adding a second receptor target has not removed the need to assess unwanted effects alongside the intended ones. Greater effectiveness and fewer side effects remain separate questions.

GIP has also been investigated as a possible way to improve tolerability. In a small experiment involving 32 treated volunteers, researchers gave an experimental long-acting GIP receptor agonist or placebo before rapidly increasing doses of liraglutide, a GLP-1 receptor agonist. There were 41 gastrointestinal events with the GIP agonist, compared with 75 when liraglutide was given with placebo. However, the proportion of participants experiencing at least one event was not significantly different. That distinction matters because one person can report more than one event: fewer total events does not necessarily establish that fewer people are affected. The experiment offers an early human signal worth investigating, but it was brief, used a different drug combination, and increased liraglutide unusually quickly. It cannot establish that tirzepatide generally causes fewer side effects than semaglutide.

Improving tolerability is also different from improving overall safety. A medicine that causes less nausea or fewer digestive symptoms would not necessarily carry a lower risk of serious adverse effects, and the small, short-duration studies discussed here cannot establish that broader safety profile. This distinction places an important limit on the idea of successive drug generations. Adding receptor targets expands the possibilities for treatment, but the value of that expansion ultimately depends on the balance of benefits, unwanted effects, and risks demonstrated in human studies. The ambition is to develop medicines that achieve better outcomes with fewer burdens for the people taking them, although each part of that ambition requires its own evidence.

Returning to that lunch-table conversation, the difference between semaglutide and tirzepatide is now easier to understand. Both medicines draw on the body's natural hormone systems, but they represent different approaches to influencing those systems. The important development is not simply that researchers have found another way to reduce appetite or body weight. They've begun exploring how several related physiological pathways might be influenced together, recognizing that the resulting effects depend on interactions that cannot always be predicted from the individual components. Understanding those interactions provides a more useful way to evaluate emerging treatments than assuming that each new drug must be a stronger version of the one before it.

The next step in this series takes us to retatrutide, an investigational medicine designed to activate three receptors: GIP, GLP-1, and glucagon. It is not FDA-approved at the time of writing, and introducing a third hormone pathway raises another set of questions about how these systems interact. Glucagon has physiological effects that differ from those of GLP-1 and GIP, making its inclusion particularly interesting. Understanding why researchers would deliberately activate all three receptors, and what human studies reveal about the resulting effects, will be the focus of our next article.

It emerges from how multiple systems interact and adapt over time, often in ways that aren’t obvious when viewed in isolation.

If you want a clearer way to think about that, I’ve outlined the systems perspective in a short guide you can download here:

The Midlife Health Reset — 10 core systems that shape strength, energy, and long-term health after 50.

Sources

Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J. (2010). Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes, 59(9), 2160-2163.

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019). Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: A randomised, crossover study. Diabetologia, 62(4), 665-675.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., & Knop, F. K. (2020). GIP and GLP-1 receptor antagonism during a meal in healthy individuals. The Journal of Clinical Endocrinology & Metabolism, 105(3), e725-e738.

Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., & Milicevic, Z. (2022). Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology, 10(6), 418-429.

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216.

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024). A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes, Obesity and Metabolism, 26(11), 5474-5478.

Martin, C. K., Carmichael, O. T., Carnell, S., Considine, R. V., Kareken, D. A., Dydak, U., Mattes, R. D., Scott, D., Shcherbinin, S., Nishiyama, H., Knights, A., Urva, S., Biernat, L., Pratt, E., Haupt, A., Mintun, M., Otero Svaldi, D., Milicevic, Z., & Coskun, T. (2025). Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial. Nature Medicine, 31(9), 3141-3150.

Roell, W., Alsina-Fernandez, J., Qu, H., Coskun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L., Sloop, K. W., Steele, J. P., Ficorilli, J., Regmi, A., Rettiganti, M., Urva, S., Mather, K. J., & Pratt, E. (2026). Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. Molecular Metabolism, 103, Article 102298.